Evidence map›Paper›PMID 32334570›Full record

ArticleBMC cancer2020

Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution.

Sandra Sauer, Petra Pavel, Anita Schmitt, Martin Cremer, Mark Kriegsmann, Thomas Bruckner, Karin Jordan, Patrick Wuchter, Carsten Müller-Tidow, Katharina Kriegsmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sandra SauerDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. sandra.sauer@med.uni-heidelberg.de.
Petra PavelStem Cell Laboratory, IKTZ Heidelberg GmbH, Heidelberg, Germany.
Anita SchmittDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Martin CremerDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Mark KriegsmannInstitute of Pathology, Heidelberg University, Heidelberg, Germany.
Thomas BrucknerInstitute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany.
Karin JordanDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Patrick WuchterInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.
Carsten Müller-TidowDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Katharina KriegsmannDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Heidelberg University · DEHeidelberg Institute for Stem Cell Technology and Experimental Medicine · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-dose (HD) chemotherapy followed by autologous blood stem-cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM) patients. However, the collection of sufficient peripheral blood stem cell (PBSC) grafts can be challenging, and the question arises whether reinfusion of low-dose grafts will lead to a hematopoietic recovery.

methodsThe hematopoietic recovery of 148 MM patients who underwent HD melphalan chemotherapy and received PBSC transplants with varying CD34+ cells doses (3-4 × 10

resultsAll patients reached hematopoietic reconstitution, even those who received < 2 × 10

conclusionIn conclusion, reinfusion of low- and even very-low-dose PBSC grafts leads to sufficient hematopoietic reconstitution. No severe adverse events were observed during or after HD chemotherapy and ASCT in the analyzed cohort. While the impact of CD34+ cell dose is marginal, G-CSF significantly accelerates the leukocyte recovery.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleFollow-Up StudiesHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansMaleMiddle AgedMultiple MyelomaPeripheral Blood Stem CellsPeripheral Blood Stem Cell TransplantationPrognosisRetrospective StudiesAutologous stem-cell transplantationInsufficient graftMultiple myelomaPeripheral blood stem cells

Identifiers

PMID32334570
PMCPMC7183692
OpenAlexW3019307888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.